Athelas, a California-based healthtech company specializing in AI-powered diagnostics, has secured 510(k) clearance from the US Food and Drug Administration for its next-generation point-of-care testing platform. The clearance significantly expands the use cases for Athelas Home, moving it from limited home monitoring to full point-of-care diagnostic settings across clinics, pharmacies, skilled nursing facilities, and telehealth-integrated home care.

The device requires only a small capillary blood sample (finger prick) and uses advanced computer vision and machine learning algorithms to analyze cellular morphology and biomarker concentrations. It delivers results in minutes for: Complete Blood Count (CBC) with differential C-Reactive Protein (CRP) for inflammation and infection assessment Lipid panels and other metabolic markers

Key advantages highlighted in the clearance include high accuracy comparable to central lab analyzers, minimal training required for operators, built-in quality controls, and seamless integration with EHRs and remote monitoring platforms. This makes the system particularly valuable for managing chronic conditions, post-discharge monitoring, and rapid triage in non-hospital settings.

The FDA clearance follows successful clinical validation studies demonstrating performance across diverse patient populations. Athelas plans rapid commercial rollout in the US, targeting partnerships with health systems, home health agencies, primary care networks, and value-based care organizations.

The milestone strengthens Athelas’ position in the fast-growing point-of-care diagnostics market, where speed, accessibility, and cost-effectiveness are driving adoption especially for decentralized care models.